- Home
- BLRX vs ALUR Comparison
BLRX vs ALUR Comparison
Compare BLRX & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- ALUR
- Stock Information
- Founded
- BLRX 2003
- ALUR 2009
- Country
- BLRX Israel
- ALUR United States
- Employees
- BLRX N/A
- ALUR N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- ALUR
- Sector
- BLRX Health Care
- ALUR
- Exchange
- BLRX Nasdaq
- ALUR Nasdaq
- Market Cap
- BLRX 17.1M
- ALUR 15.4M
- IPO Year
- BLRX 2011
- ALUR N/A
- Fundamental
- Price
- BLRX $3.47
- ALUR $1.85
- Analyst Decision
- BLRX Strong Buy
- ALUR Buy
- Analyst Count
- BLRX 2
- ALUR 2
- Target Price
- BLRX $19.00
- ALUR $9.25
- AVG Volume (30 Days)
- BLRX 29.9K
- ALUR 51.6K
- Earning Date
- BLRX 11-24-2025
- ALUR 11-13-2025
- Dividend Yield
- BLRX N/A
- ALUR N/A
- EPS Growth
- BLRX N/A
- ALUR N/A
- EPS
- BLRX N/A
- ALUR N/A
- Revenue
- BLRX $17,251,000.00
- ALUR $19,917,000.00
- Revenue This Year
- BLRX N/A
- ALUR N/A
- Revenue Next Year
- BLRX N/A
- ALUR N/A
- P/E Ratio
- BLRX N/A
- ALUR N/A
- Revenue Growth
- BLRX 1.19
- ALUR N/A
- 52 Week Low
- BLRX $2.30
- ALUR $1.79
- 52 Week High
- BLRX $22.60
- ALUR $19.69
- Technical
- Relative Strength Index (RSI)
- BLRX 37.37
- ALUR 36.32
- Support Level
- BLRX $3.51
- ALUR $1.79
- Resistance Level
- BLRX $3.89
- ALUR $2.03
- Average True Range (ATR)
- BLRX 0.22
- ALUR 0.10
- MACD
- BLRX -0.05
- ALUR -0.01
- Stochastic Oscillator
- BLRX 17.85
- ALUR 19.43
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.